MBX Biosciences, Inc.(MBX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Topline results for the Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in Q3 2025 MBX 4291 Phase 1 trial initiation in obesity anticipated in Q3 2025 $224.9 million in cash, cash equivalents and marketable securities as of June 30, 2025; expected to support operatio ...